نتایج جستجو برای: tp53 mutation and expression

تعداد نتایج: 16973495  

2011
Julia Mohr Hanne Helfrich Maxi Fuge Eric Eldering Andreas Bühler Dirk Winkler Matthias Volden Arnon P. Kater Daniel Mertens Doreen Te Raa Hartmut Döhner Stephan Stilgenbauer Thorsten Zenz

The DNA damage pathway plays a central role in chemoresistance in chronic lymphocytic leukemia (CLL), as indicated by the prognostic impact of TP53 and ATM loss/ mutations. We investigated the function of the p53 axis in primary CLL samples by studying p53 and p21 responses to irradiation by FACS and RT-PCR. We observed a distinct response pattern for most cases with a 17p deletion (n 16) or a ...

2015
A M Hurtado T-H Chen-Liang B Przychodzen C Hamedi J Muñoz-Ballester B Dienes M D García-Malo A I Antón F de Arriba R Teruel-Montoya F J Ortuño V Vicente J P Maciejewski A Jerez

An increasing numbers of patients are being diagnosed with asymptomatic early-stage chronic lymphocytic leukemia (CLL), with no treatment indication at baseline. We applied a high-throughput deep-targeted analysis, especially designed for covering widely TP53 and ATM genes, in 180 patients with inactive disease at diagnosis, to test the independent prognostic value of CLL somatic recurrent muta...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2014
Laxmi Silwal-Pandit Hans Kristian Moen Vollan Suet-Feung Chin Oscar M Rueda Steven McKinney Tomo Osako David A Quigley Vessela N Kristensen Samuel Aparicio Anne-Lise Børresen-Dale Carlos Caldas Anita Langerød

PURPOSE In breast cancer, the TP53 gene is frequently mutated and the mutations have been associated with poor prognosis. The prognostic impact of the different types of TP53 mutations across the different molecular subtypes is still poorly understood. Here, we characterize the spectrum and prognostic significance of TP53 mutations with respect to the PAM50 subtypes and integrative clusters (IC...

2016
George Fountzilas Eleni Giannoulatou Zoi Alexopoulou Flora Zagouri Eleni Timotheadou Kyriaki Papadopoulou Sotiris Lakis Mattheos Bobos Christos Poulios Maria Sotiropoulou Aggeliki Lyberopoulou Helen Gogas George Pentheroudakis Dimitrios Pectasides Angelos Koutras Christos Christodoulou Christos Papandreou Epaminontas Samantas Pavlos Papakostas Paris Kosmidis Dimitrios Bafaloukos Charisios Karanikiotis Meletios-Athanassios Dimopoulos Vassiliki Kotoula

BACKGROUND We investigated the impact of PIK3CA and TP53 mutations and p53 protein status on the outcome of patients who had been treated with adjuvant anthracycline-taxane chemotherapy within clinical trials in the pre- and post-trastuzumab era. RESULTS TP53 and PIK3CA mutations were found in 380 (21.5%) and 458 (25.9%) cases, respectively, including 104 (5.9%) co-mutated tumors; p53 immunop...

2017
Eric J. Devor Jesus Gonzalez-Bosquet Akshaya Warrier Henry D. Reyes Nonye V. Ibik Brandon M. Schickling Andreea Newtson Michael J. Goodheart Kimberly K. Leslie

Placenta-specific protein 1 (PLAC1) expression is co-opted in numerous human cancers. As a consequence of PLAC1 expression, tumor cells exhibit enhanced proliferation and invasiveness. This characteristic is associated with increased aggressiveness and worse patient outcomes. Recently, the presence of the tumor suppressor p53 was shown in vitro to inhibit PLAC1 transcription by compromising the...

2017
Wensheng Zhang Andrea Edwards Erik K Flemington Kun Zhang

TP53 is the most frequently altered gene in human cancers. Numerous retrospective studies have related its mutation and abnormal p53 protein expression to poor patient survival. Nonetheless, the clinical significance of TP53 (p53) status has been a controversial issue. In this work, we aimed to characterize TP53 somatic mutations in tumor cells across multiple cancer types, primarily focusing o...

2014
Mariana Maschietto Richard D. Williams Tasnim Chagtai Sergey D. Popov Neil J. Sebire Gordan Vujanic Elizabeth Perlman James R. Anderson Paul Grundy Jeffrey S. Dome Kathy Pritchard-Jones Keith William Brown

PURPOSE The presence of diffuse anaplasia in Wilms tumours (DAWT) is associated with TP53 mutations and poor outcome. As patients receive intensified treatment, we sought to identify whether TP53 mutational status confers additional prognostic information. PATIENTS AND METHODS We studied 40 patients with DAWT with anaplasia in the tissue from which DNA was extracted and analysed for TP53 muta...

Journal: :Molecular cancer research : MCR 2015
David Quigley Laxmi Silwal-Pandit Ruth Dannenfelser Anita Langerød Hans Kristian Moen Vollan Charles Vaske Josie Ursini Siegel Olga Troyanskaya Suet-Feung Chin Carlos Caldas Allan Balmain Anne-Lise Børresen-Dale Vessela Kristensen

UNLABELLED Lymphocytic infiltration is associated with better prognosis in several epithelial malignancies including breast cancer. The tumor suppressor TP53 is mutated in approximately 30% of breast adenocarcinomas, with varying frequency across molecular subtypes. In this study of 1,420 breast tumors, we tested for interaction between TP53 mutation status and tumor subtype determined by PAM50...

Journal: :The Journal of biological chemistry 2010
Jim Jinn-Chyuan Sheu Bin Guan Jung-Hye Choi Athena Lin Chia-Huei Lee Yi-Ting Hsiao Tian-Li Wang Fuu-Jen Tsai Ie-Ming Shih

Rsf-1 (HBXAP) has been reported as an amplified gene in human cancer, including the highly aggressive ovarian serous carcinoma. Rsf-1 protein interacts with SNF2H to form an ISWI chromatin remodeling complex, RSF. In this study, we investigated the functional role of Rsf-1 by observing phenotypes after expressing it in nontransformed cells. Acute expression of Rsf-1 resulted in DNA damage as ev...

Journal: :Asian Pacific journal of cancer prevention : APJCP 2014
Kai Wang Yin-Yan Wang Jun Ma Jiang-Fei Wang Shao-Wu Li Tao Jiang Jian-Ping Dai

Several molecular markers have been proposed as predictors of outcome in patients with glioblastomas. We investigated the prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and TP53 mutation status dependent on isocitrate dehydrogenase 1 (IDH1) mutation in glioblastoma patients. A cohort of 78 patients with histologically confirmed glioblastomas treate...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید